Abstract
Background kidney and cardiovascular diseases are responsible for a large fraction of population morbidity and mortality. Early, targeted, personalized intervention represents the ideal approach to cope with this challenge. Proteomic/peptidomic changes are largely responsible for onset and progression of these diseases and should hold information about optimal means for treatment and prevention.
Methods we investigated prediction of renal or cardiovascular events using previously defined urinary peptidomic classifiers CKD273, HF2 and CAD160 in a cohort of 5585 subjects in a retrospective study.
Results we demonstrate highly significant prediction of events with HR of 2.59, 1.71, and 4.12 for HF, CAD and CKD respectively. We applied in silico treatment, implementing on each patient urinary profile, changes onto the classifiers corresponding to exactly defined peptide abundance changes following commonly used interventions (MRA, SGLT2i, DPP4i, ARB, GLP1RA, olive oil and exercise), as defined in previous studies. Applying the proteomic classifiers after in silico treatment indicated individual benefits of specific interventions on a personalized level.
Conclusions the in-silico evaluation may provide information on the future impact of specific drugs and intervention on endpoints, opening the door to a precision medicine approach. Investigation of the extent of the benefit of this approach in a prospective clinical trial is warranted.
Competing Interest Statement
H. Mischak is the founder and co-owner of Mosaiques Diagnostics (Hannover. Germany). M. Jaimes. J. Siwy and A. Latosinska are employed by Mosaiques Diagnostics. PR has received grants from Astra Zeneca. Bayer and Novo Nordisk and honoraria (to Steno Diabetes Center Copenhagen) from Astra Zeneca. Abbott. Bayer. Boehringer Ingelheim. Eli Lilly. Novo Nordisk. Gilead. and Sanofi. AO has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene. Alexion. Astellas. Astrazeneca. Amicus. Amgen. Boehringer Ingelheim. Fresenius Medical Care. GSK. Bayer. Sanofi-Genzyme. Menarini. Mundipharma. Kyowa Kirin. Lilly. Freeline. Idorsia. Chiesi. Otsuka. Novo-Nordisk. Sysmex and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes. He has stock in Telara Farma. F.P. has served as a consultant on advisory boards or as an educator for Astra Zeneca, Novo Nordisk, Sanofi, Mundipharma, MSD, Boehringer Ingelheim, Novartis, and Amgen, and has received research grants to institution from Novo Nordisk, Amgen, and Astra Zeneca. All other authors have no potential conflicts of interest.
Funding Statement
Funding for this project was provided in part by the German ministry for education and science (BMBF) via grant 01DN21014 to HM, JS and AL. Additional funding was provided by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848011 for the DC–ren project. MAJC was supported by the European Union’s Horizon Europe Marie Skłodowska–Curie Actions Doctoral Networks – Industrial Doctorates Programme (HORIZON – MSCA – 2021 – DN–ID. grant number 101072828). AO research is supported by FIS–Fondos FEDER ERA–PerMed–JTC2022 (SPAREKID AC22/00027). Comunidad de Madrid en Biomedicina P2022–BMD–7223. CIFRA–COR–CM. Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union – NextGenerationEU. Mecanismo para la Recuperación y la Resiliencia (MRR) and SPACKDc PMP21–00109. FEDER funds. COST Action PERMEDIK CA21165. supported by COST (European Cooperation in Science and Technology). PREVENTCKD Consortium. Project ID: 101101220 Programme: EU4H. DG–Agency: HADEA. JJ was supported by grants from the German Research Foundation (DFG) (SFB–TRR 219 project–ID: 322900939 and SFB 1382 Project–ID 403224013) as well as by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska–Curie grant agreement No 764474 (CaReSyAn) and No 860329 (Strategy–CKD).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Hannover Medical School Germany under the reference number 3116-2016.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
jaimes{at}mosaiques-diagnostics.com (M.A.J.C.); mischak{at}mosaiques.de (H.M.); siwy{at}mosaiques-diagnostics.com (J.S.); latosinska{at}mosaiques-diagnostics.com (A.L.)
jjankowski{at}ukaachen.de
gert.mayer{at}i-med.ac.at (G.M.); felix.keller{at}i-med.ac.at (F.K.)
peter.rossing{at}regionh.dk (P.R);
jan.staessen{at}appremed.org
Christian.Delles{at}glasgow.ac.uk (C.D.); william.mullen{at}glasgow.ac.uk (W.M.)
Joachim.Beige{at}kfh.de
griet.glorieux{at}ugent.be
A.L.Clark{at}hull.ac.uk
joost-peter.schanstra{at}inserm.fr
vlahoua{at}bioacademy.gr
kasper.rossing{at}regionh.dk
karlheinz.peter{at}baker.edu.au
aortiz{at}fjd.es
archie.campbell{at}ed.ac.uk
Data Availability
All data produced in the present work are contained in the manuscript